Do analysts recommend MGRX or AIDX?

20/20 Biolabs has a consensus price target of $5.00, indicating a potential upside of 792.86%. Given 20/20 Biolabs' stronger consensus rating and higher probable upside, analysts plainly believe 20/20 Biolabs is more favorable than Mangoceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 20/20 Biolabs 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend MGRX or BMGL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Basel Medical Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, MGRX or BMGL?

Basel Medical Group has higher revenue and earnings than Mangoceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mangoceuticals $460K 18.89 -$20.64M -$1.01 N/A Basel Medical Group $8.90M 0.82 -$9.50M N/A N/A

Does the media favor MGRX or BMGL?

In the previous week, Mangoceuticals had 1 more articles in the media than Basel Medical Group. MarketBeat recorded 3 mentions for Mangoceuticals and 2 mentions for Basel Medical Group. Mangoceuticals' average media sentiment score of 0.96 beat Basel Medical Group's score of 0.94 indicating that Mangoceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mangoceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Basel Medical Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend GXAI or MGRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gaxos.ai 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is GXAI or MGRX more profitable?

Gaxos.ai has a net margin of -64.81% compared to Mangoceuticals' net margin of -4,794.60%. Gaxos.ai's return on equity of -38.79% beat Mangoceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Gaxos.ai -64.81% -38.79% -36.99% Mangoceuticals -4,794.60% -96.39% -89.60%

Do analysts rate BIAF or MGRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score bioAffinity Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer BIAF or MGRX?

In the previous week, bioAffinity Technologies had 1 more articles in the media than Mangoceuticals. MarketBeat recorded 4 mentions for bioAffinity Technologies and 3 mentions for Mangoceuticals. bioAffinity Technologies' average media sentiment score of 1.01 beat Mangoceuticals' score of 0.96 indicating that bioAffinity Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment bioAffinity Technologies 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mangoceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer IVF or MGRX?

INVO Fertility presently has a consensus price target of $20.00, suggesting a potential upside of 1,963.77%. Given INVO Fertility's stronger consensus rating and higher possible upside, equities analysts plainly believe INVO Fertility is more favorable than Mangoceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INVO Fertility 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Mangoceuticals (MGRX) Competitors

$0.40 +0.02 (+4.62%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$0.40 0.00 (-0.70%)

As of 09/11/2026 07:33 PM Eastern

Compare

MGRX vs. AIDX, BMGL, GXAI, BIAF, and IVF

Should you buy Mangoceuticals stock or one of its competitors? Mangoceuticals's main competitors and comparable companies include 20/20 Biolabs (AIDX), Basel Medical Group (BMGL), Gaxos.ai (GXAI), bioAffinity Technologies (BIAF), and INVO Fertility (IVF). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Mangoceuticals compare to 20/20 Biolabs?

Mangoceuticals (NASDAQ:MGRX) and 20/20 Biolabs (NASDAQ:AIDX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.

In the previous week, Mangoceuticals had 2 more articles in the media than 20/20 Biolabs. MarketBeat recorded 3 mentions for Mangoceuticals and 1 mentions for 20/20 Biolabs. 20/20 Biolabs' average media sentiment score of 1.87 beat Mangoceuticals' score of 0.96 indicating that 20/20 Biolabs is being referred to more favorably in the news media.

Company	Overall Sentiment
Mangoceuticals	Positive
20/20 Biolabs	Very Positive

20/20 Biolabs has a consensus price target of $5.00, indicating a potential upside of 792.86%. Given 20/20 Biolabs' stronger consensus rating and higher probable upside, analysts plainly believe 20/20 Biolabs is more favorable than Mangoceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
20/20 Biolabs	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

56.7% of Mangoceuticals shares are owned by institutional investors. 16.0% of Mangoceuticals shares are owned by insiders. Comparatively, 29.8% of 20/20 Biolabs shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

20/20 Biolabs has higher revenue and earnings than Mangoceuticals. 20/20 Biolabs is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mangoceuticals	$460K	18.89	-$20.64M	-$1.01	N/A
20/20 Biolabs	$2.05M	3.49	-$3.74M	-$0.54	N/A

20/20 Biolabs has a net margin of 0.00% compared to Mangoceuticals' net margin of -4,794.60%. 20/20 Biolabs' return on equity of 0.00% beat Mangoceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mangoceuticals	-4,794.60%	-96.39%	-89.60%
20/20 Biolabs	N/A	N/A	N/A

Summary

20/20 Biolabs beats Mangoceuticals on 11 of the 15 factors compared between the two stocks.

How does Mangoceuticals compare to Basel Medical Group?

Mangoceuticals (NASDAQ:MGRX) and Basel Medical Group (NASDAQ:BMGL) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Basel Medical Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Basel Medical Group has a net margin of 0.00% compared to Mangoceuticals' net margin of -4,794.60%. Basel Medical Group's return on equity of 0.00% beat Mangoceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mangoceuticals	-4,794.60%	-96.39%	-89.60%
Basel Medical Group	N/A	N/A	N/A

Mangoceuticals has a beta of 2.04, indicating that its share price is 104% more volatile than the broader market. Comparatively, Basel Medical Group has a beta of 0.26, indicating that its share price is 74% less volatile than the broader market.

In the previous week, Mangoceuticals had 1 more articles in the media than Basel Medical Group. MarketBeat recorded 3 mentions for Mangoceuticals and 2 mentions for Basel Medical Group. Mangoceuticals' average media sentiment score of 0.96 beat Basel Medical Group's score of 0.94 indicating that Mangoceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mangoceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Basel Medical Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

56.7% of Mangoceuticals shares are held by institutional investors. 16.0% of Mangoceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Basel Medical Group has higher revenue and earnings than Mangoceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mangoceuticals	$460K	18.89	-$20.64M	-$1.01	N/A
Basel Medical Group	$8.90M	0.82	-$9.50M	N/A	N/A

Summary

Mangoceuticals beats Basel Medical Group on 6 of the 11 factors compared between the two stocks.

How does Mangoceuticals compare to Gaxos.ai?

Gaxos.ai (NASDAQ:GXAI) and Mangoceuticals (NASDAQ:MGRX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

42.6% of Gaxos.ai shares are owned by institutional investors. Comparatively, 56.7% of Mangoceuticals shares are owned by institutional investors. 3.2% of Gaxos.ai shares are owned by company insiders. Comparatively, 16.0% of Mangoceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Mangoceuticals had 1 more articles in the media than Gaxos.ai. MarketBeat recorded 3 mentions for Mangoceuticals and 2 mentions for Gaxos.ai. Gaxos.ai's average media sentiment score of 1.43 beat Mangoceuticals' score of 0.96 indicating that Gaxos.ai is being referred to more favorably in the media.

Company	Overall Sentiment
Gaxos.ai	Positive
Mangoceuticals	Positive

Gaxos.ai has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market. Comparatively, Mangoceuticals has a beta of 2.04, meaning that its stock price is 104% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gaxos.ai	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Gaxos.ai has higher revenue and earnings than Mangoceuticals. Gaxos.ai is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gaxos.ai	$1.93M	2.51	-$3.90M	-$0.50	N/A
Mangoceuticals	$460K	18.89	-$20.64M	-$1.01	N/A

Gaxos.ai has a net margin of -64.81% compared to Mangoceuticals' net margin of -4,794.60%. Gaxos.ai's return on equity of -38.79% beat Mangoceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gaxos.ai	-64.81%	-38.79%	-36.99%
Mangoceuticals	-4,794.60%	-96.39%	-89.60%

Summary

Gaxos.ai beats Mangoceuticals on 7 of the 13 factors compared between the two stocks.

How does Mangoceuticals compare to bioAffinity Technologies?

bioAffinity Technologies (NASDAQ:BIAF) and Mangoceuticals (NASDAQ:MGRX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, media sentiment, institutional ownership and profitability.

bioAffinity Technologies has a beta of -1.11, indicating that its stock price is 211% less volatile than the broader market. Comparatively, Mangoceuticals has a beta of 2.04, indicating that its stock price is 104% more volatile than the broader market.

1.6% of bioAffinity Technologies shares are held by institutional investors. Comparatively, 56.7% of Mangoceuticals shares are held by institutional investors. 2.7% of bioAffinity Technologies shares are held by insiders. Comparatively, 16.0% of Mangoceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

bioAffinity Technologies has a net margin of -257.30% compared to Mangoceuticals' net margin of -4,794.60%. Mangoceuticals' return on equity of -96.39% beat bioAffinity Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
bioAffinity Technologies	-257.30%	-220.52%	-136.76%
Mangoceuticals	-4,794.60%	-96.39%	-89.60%

In the previous week, bioAffinity Technologies had 1 more articles in the media than Mangoceuticals. MarketBeat recorded 4 mentions for bioAffinity Technologies and 3 mentions for Mangoceuticals. bioAffinity Technologies' average media sentiment score of 1.01 beat Mangoceuticals' score of 0.96 indicating that bioAffinity Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
bioAffinity Technologies	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mangoceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
bioAffinity Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

bioAffinity Technologies has higher revenue and earnings than Mangoceuticals. Mangoceuticals is trading at a lower price-to-earnings ratio than bioAffinity Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
bioAffinity Technologies	$6.16M	0.77	-$14.91M	-$109.45	N/A
Mangoceuticals	$460K	18.89	-$20.64M	-$1.01	N/A

Summary

Mangoceuticals beats bioAffinity Technologies on 7 of the 13 factors compared between the two stocks.

How does Mangoceuticals compare to INVO Fertility?

INVO Fertility (NASDAQ:IVF) and Mangoceuticals (NASDAQ:MGRX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

12.0% of INVO Fertility shares are owned by institutional investors. Comparatively, 56.7% of Mangoceuticals shares are owned by institutional investors. 0.4% of INVO Fertility shares are owned by company insiders. Comparatively, 16.0% of Mangoceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Mangoceuticals has lower revenue, but higher earnings than INVO Fertility. Mangoceuticals is trading at a lower price-to-earnings ratio than INVO Fertility, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INVO Fertility	$6.84M	0.36	-$25.13M	-$33.83	N/A
Mangoceuticals	$460K	18.89	-$20.64M	-$1.01	N/A

INVO Fertility presently has a consensus price target of $20.00, suggesting a potential upside of 1,963.77%. Given INVO Fertility's stronger consensus rating and higher possible upside, equities analysts plainly believe INVO Fertility is more favorable than Mangoceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INVO Fertility	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

INVO Fertility has a net margin of -116.29% compared to Mangoceuticals' net margin of -4,794.60%. INVO Fertility's return on equity of -85.54% beat Mangoceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INVO Fertility	-116.29%	-85.54%	-31.05%
Mangoceuticals	-4,794.60%	-96.39%	-89.60%

In the previous week, Mangoceuticals had 1 more articles in the media than INVO Fertility. MarketBeat recorded 3 mentions for Mangoceuticals and 2 mentions for INVO Fertility. Mangoceuticals' average media sentiment score of 0.96 beat INVO Fertility's score of 0.30 indicating that Mangoceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
INVO Fertility	Neutral
Mangoceuticals	Positive

INVO Fertility has a beta of 2.34, suggesting that its share price is 134% more volatile than the broader market. Comparatively, Mangoceuticals has a beta of 2.04, suggesting that its share price is 104% more volatile than the broader market.

Summary

INVO Fertility beats Mangoceuticals on 9 of the 16 factors compared between the two stocks.

Get Mangoceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MGRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MGRX vs. The Competition

Export

Metric	Mangoceuticals	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$8.69M	$9.84B	$7.16B	$12.85B
Dividend Yield	N/A	2.61%	2.57%	11.17%
P/E Ratio	-0.40	33.53	274.94	25.36
Price / Sales	18.89	4.89	686.01	116.83
Price / Cash	N/A	125.15	76.65	51.52
Price / Book	0.43	5.29	10.33	6.20
Net Income	-$20.64M	$313.25M	$3.50B	$358.50M
7 Day Performance	-2.00%	-1.26%	-3.32%	-2.35%
1 Month Performance	-24.46%	-1.53%	-0.53%	-3.23%
1 Year Performance	-82.26%	58.44%	23.51%	8.79%

Mangoceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MGRX Mangoceuticals	1.1196 of 5 stars	$0.40 +4.6%	N/A	-82.3%	$8.69M	$460K	N/A	3	News Coverage Short Interest Decrease
AIDX 20/20 Biolabs	2.816 of 5 stars	$0.57 +5.5%	$5.00 +777.2%	N/A	$7.36M	$2.05M	N/A	14	News Coverage
BMGL Basel Medical Group	0.6769 of 5 stars	$4.69 +2.3%	N/A	-80.3%	$7.31M	$8.90M	N/A	36	News Coverage Positive News Analyst Downgrade Gap Down
GXAI Gaxos.ai	0.8242 of 5 stars	$0.70 -6.5%	N/A	-60.5%	$4.95M	$1.93M	N/A	3	Short Interest Decrease
BIAF bioAffinity Technologies	0.9285 of 5 stars	$8.04 -14.4%	N/A	-93.5%	$4.89M	$6.16M	N/A	10	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MGRX) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mangoceuticals (MGRX) Competitors

MGRX vs. AIDX, BMGL, GXAI, BIAF, and IVF

How does Mangoceuticals compare to 20/20 Biolabs?

Summary

How does Mangoceuticals compare to Basel Medical Group?

Summary

How does Mangoceuticals compare to Gaxos.ai?

Summary

How does Mangoceuticals compare to bioAffinity Technologies?

Summary

How does Mangoceuticals compare to INVO Fertility?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGRX vs. The Competition

Mangoceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mangoceuticals (MGRX) Competitors

MGRX vs. AIDX, BMGL, GXAI, BIAF, and IVF

How does Mangoceuticals compare to 20/20 Biolabs?

Does the media favor MGRX or AIDX?

Do analysts recommend MGRX or AIDX?

Do institutionals and insiders have more ownership in MGRX or AIDX?

Which has stronger earnings & valuation, MGRX or AIDX?

Is MGRX or AIDX more profitable?

Summary

How does Mangoceuticals compare to Basel Medical Group?

Do analysts recommend MGRX or BMGL?

Is MGRX or BMGL more profitable?

Which has more volatility & risk, MGRX or BMGL?

Does the media favor MGRX or BMGL?

Do insiders and institutionals hold more shares of MGRX or BMGL?

Which has stronger earnings and valuation, MGRX or BMGL?

Summary

How does Mangoceuticals compare to Gaxos.ai?

Do insiders & institutionals hold more shares of GXAI or MGRX?

Does the media prefer GXAI or MGRX?

Which has more risk and volatility, GXAI or MGRX?

Do analysts recommend GXAI or MGRX?

Which has stronger valuation and earnings, GXAI or MGRX?

Is GXAI or MGRX more profitable?

Summary

How does Mangoceuticals compare to bioAffinity Technologies?

Which has more risk and volatility, BIAF or MGRX?

Do insiders and institutionals have more ownership in BIAF or MGRX?

Is BIAF or MGRX more profitable?

Does the media prefer BIAF or MGRX?

Do analysts rate BIAF or MGRX?

Which has stronger earnings and valuation, BIAF or MGRX?

Summary

How does Mangoceuticals compare to INVO Fertility?

Do insiders & institutionals have more ownership in IVF or MGRX?

Which has stronger earnings & valuation, IVF or MGRX?

Do analysts prefer IVF or MGRX?

Is IVF or MGRX more profitable?

Does the media refer more to IVF or MGRX?

Which has more volatility & risk, IVF or MGRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGRX vs. The Competition

Mangoceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools